SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

8 Oct 2013 07:00

RNS Number : 9350P
Victrex PLC
08 October 2013
 



 

 

8 October 2013

Victrex plc - Year End Trading Statement

Victrex plc ('Victrex'), an innovative world leader in high performance polymers, today releases its year end trading statement, ahead of its 2013 preliminary results which will be announced on Tuesday 10 December 2013.

Full year sales volume was slightly ahead of last year at 2,920 tonnes (FY 2012: 2,904 tonnes) following a robust second half performance, with sales volume approximately 10% ahead of the first half year. Group sales volume of 1,528 tonnes for the second half was in line with the strong prior year performance (H2 2012: 1,527 tonnes), with good progress across our industrial and transport markets, offset by lower sales in the electronics market following the non-recurrence of last year's strong product launch related sales into consumer electronics.

In our Invibio Biomaterial Solutions business, full year revenue was slightly ahead of the prior year at £50.8m (FY 2012: £50.5m). This reflects steady improvement in sales to the Spine market during the second half year, with revenue 10% ahead of the first half, as inventory levels in the industry appear to have stabilised. Second half revenue in Invibio was also ahead of the prior year at £26.6m (H2 2012: £25.0m). Outside of the Spine market, we continue to see steady progress in our emerging market opportunities.

Outlook

Looking ahead to our new financial year, whilst we remain mindful of the wider economic environment, our order book for October is reassuring. Victrex remains confident in the diverse and multiple growth opportunities that are being developed across the business. Our investment in additional capacity, which is a key enabler to support and deliver our future growth programmes, remains on plan and on budget, with construction progressing well.

Victrex will host an Investor Day, 'Spotlight on Growth', in London this Thursday, 10 October 2013, with its Executive Management Team, including presentations by Tim Cooper, Managing Director of VPS, and Martin Court, Managing Director of Invibio, covering the scale of Victrex's Group wide growth programmes. No new trading or financial information will be disclosed during the Investor Day. 

 

Enquiries:

Victrex plc:

Andrew Hanson, Head of Investor Relations 01253 898121

Steve Barrow, Group Finance Director 01253 897700

 

MHP Communications:

Nick Denton/Barnaby Fry/James White 0203 128 8100

 

Investor and analyst conference call:

A conference call for Investors and Analysts will be held today, Tuesday 8 October, 09.00am. For further details please contact Ben Griffiths at MHP Communications on 0203 128 8100.

 

About Victrex:

Victrex is an innovative world leader in high performance polymers. Every day, millions of people rely on products or applications which contain our materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 30 years' experience, we are investing in technology leadership to deliver new solutions to our customers and our markets. Find out more at www.victrexplc.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGWAUUPWGQM
Date   Source Headline
27th Feb 201510:00 amRNSTotal Voting Rights
26th Feb 20154:53 pmRNSHolding(s) in Company
25th Feb 20154:43 pmRNSHolding(s) in Company
19th Feb 20153:03 pmRNSDirector/PDMR Shareholding
17th Feb 20152:25 pmRNSDirector/PDMR Shareholding
4th Feb 20153:59 pmRNSResult of AGM
4th Feb 20157:00 amRNSAGM and Q1 Interim Management Statement
30th Jan 20152:00 pmRNSTotal Voting Rights
26th Jan 201512:03 pmRNSDirector Declaration
19th Jan 20153:38 pmRNSDirector/PDMR Shareholding
14th Jan 20154:00 pmRNSHolding(s) in Company
5th Jan 201511:43 amRNSAnnual Financial Report
31st Dec 20147:00 amRNSTotal Voting Rights
19th Dec 20147:00 amRNSDirector Declaration
18th Dec 20148:34 amRNSDirectorate Change
18th Dec 20147:00 amRNSDirectorate Change
17th Dec 201412:45 pmRNSDirector/PDMR Shareholding
16th Dec 20145:13 pmRNSDirector/PDMR Shareholding
16th Dec 20144:43 pmRNSDirector/PDMR Shareholding
9th Dec 20147:00 amRNSFinal Results
1st Dec 20141:51 pmRNSBlocklisting Interim Review
28th Nov 201410:00 amRNSTotal Voting Rights
25th Nov 20144:30 pmRNSHolding(s) in Company
18th Nov 201411:38 amRNSDirector/PDMR Shareholding
6th Nov 201411:12 amRNSDirector Declaration
31st Oct 20149:27 amRNSTotal Voting Rights
21st Oct 20143:14 pmRNSSenior Independent Director Appointment
20th Oct 20144:38 pmRNSHolding(s) in Company
20th Oct 20149:05 amRNSDirector/PDMR Shareholding
9th Oct 20147:00 amRNSTrading Statement
1st Oct 20143:56 pmRNSDirector Disclosure Section 430 (2B)
1st Oct 20147:00 amRNSDirectorate Change
30th Sep 20141:34 pmRNSTotal Voting Rights
24th Sep 20144:12 pmRNSHolding(s) in Company
17th Sep 20141:16 pmRNSDirector/PDMR Shareholding
29th Aug 201410:00 amRNSTotal Voting Rights
19th Aug 20142:34 pmRNSDirector/PDMR Shareholding
31st Jul 20149:37 amRNSTotal Voting Rights
30th Jul 20147:00 amRNSInterim Management Statement
21st Jul 20142:13 pmRNSHolding(s) in Company
30th Jun 20142:54 pmRNSTotal Voting Rights
27th Jun 20144:00 pmRNSHolding(s) in Company
23rd Jun 201411:07 amRNSHolding(s) in Company
17th Jun 20144:04 pmRNSDirector/PDMR Shareholding
9th Jun 201411:18 amRNSBlocklisting Interim Review
4th Jun 20142:28 pmRNSDirector/PDMR Shareholding
30th May 201412:00 pmRNSTotal Voting Rights
27th May 20143:09 pmRNSDirector/PDMR Shareholding
20th May 20147:06 amRNSDirectorate Change
20th May 20147:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.